DE60220049D1 - Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer - Google Patents

Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer

Info

Publication number
DE60220049D1
DE60220049D1 DE60220049T DE60220049T DE60220049D1 DE 60220049 D1 DE60220049 D1 DE 60220049D1 DE 60220049 T DE60220049 T DE 60220049T DE 60220049 T DE60220049 T DE 60220049T DE 60220049 D1 DE60220049 D1 DE 60220049D1
Authority
DE
Germany
Prior art keywords
polymer
startering
medicament
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220049T
Other languages
English (en)
Other versions
DE60220049T2 (de
Inventor
Walter Christian Babcock
William John Curatolo
Dwayne Thomas Friesen
Rodney James Ketner
Julian Belknap Lo
James Alan NIGHTINGALE
Ravi Mysore Shanker
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60220049D1 publication Critical patent/DE60220049D1/de
Publication of DE60220049T2 publication Critical patent/DE60220049T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
DE60220049T 2001-06-22 2002-05-13 Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer Expired - Fee Related DE60220049T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30026101P 2001-06-22 2001-06-22
US300261P 2001-06-22
PCT/IB2002/001800 WO2003000294A1 (en) 2001-06-22 2002-05-13 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer

Publications (2)

Publication Number Publication Date
DE60220049D1 true DE60220049D1 (de) 2007-06-21
DE60220049T2 DE60220049T2 (de) 2007-08-30

Family

ID=23158352

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220049T Expired - Fee Related DE60220049T2 (de) 2001-06-22 2002-05-13 Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer

Country Status (11)

Country Link
US (3) US20030104063A1 (de)
EP (1) EP1401503B1 (de)
JP (1) JP2005500313A (de)
AT (1) ATE361758T1 (de)
AU (1) AU2002304387A1 (de)
BR (1) BR0210520A (de)
CA (1) CA2448864C (de)
DE (1) DE60220049T2 (de)
ES (1) ES2284871T3 (de)
MX (1) MXPA03011922A (de)
WO (1) WO2003000294A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
BR0210505A (pt) * 2001-06-21 2004-05-18 Pfizer Prod Inc Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1401503B1 (de) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
RU2005103625A (ru) * 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
PL3395338T3 (pl) 2003-09-12 2019-10-31 Amgen Inc Szybko rozpuszczająca się formulacja zawierająca cynakalcet HCl
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
WO2005105054A1 (en) * 2004-04-15 2005-11-10 Dr. Reddy's Laboratories Ltd. Dosage form having polymorphic stability
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
JP2008519062A (ja) * 2004-11-05 2008-06-05 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 個々に被覆された安定化ラミプリル粒子、組成物及び方法
WO2006064906A1 (ja) * 2004-12-17 2006-06-22 Ono Pharmaceutical Co., Ltd. 非晶質性組成物
WO2006069159A2 (en) * 2004-12-20 2006-06-29 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising amorphous benzimidazole compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
GB0502790D0 (en) * 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
JP5243247B2 (ja) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
WO2007106182A2 (en) * 2005-11-09 2007-09-20 Novartis Ag Process for making pharmaceutical compositions with a transient plasticizer
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
NZ569700A (en) 2006-02-09 2011-09-30 Merck Sharp & Dohme Polymer formulations of CETP inhibitors
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US20080221047A1 (en) 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
EP2125938A2 (de) * 2007-01-26 2009-12-02 Isp Investments Inc. Verfahren zur herstellung einer formulierung für sprühgetrocknete produkte
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
WO2008114859A1 (ja) * 2007-03-22 2008-09-25 Astellas Pharma Inc. ピラゾール誘導体を含有する医薬組成物
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
EP2240022B1 (de) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Oxycodone und Promethazine enthaltende zweischichtige Tabletten
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
RU2010139643A (ru) 2008-02-28 2012-04-10 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи к/о СиЭсСи Сервисиз оф Невада, Инк., (US) Способ минимизации полиморфизма
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
ES2594433T3 (es) * 2008-04-02 2016-12-20 Astellas Pharma Inc. Composición farmacéutica que contiene derivado de amida
EP2133068A1 (de) * 2008-06-13 2009-12-16 Ratiopharm GmbH Verfahren zur Auswahl eines geeigneten Hilfsstoffs für die Herstellung von festen Dispersionen für pharmazeutische Formulierungen
US9078808B2 (en) * 2009-03-26 2015-07-14 Warsaw Orthopedic, Inc. Device to deliver magnesium in PEG formulation
WO2010147978A1 (en) * 2009-06-16 2010-12-23 Pfizer Inc. Dosage forms of apixaban
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120065793A1 (en) 2010-02-25 2012-03-15 Kaji Mitsuru Demand and supply control apparatus, demand and supply control method, and program
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
MY165086A (en) * 2010-07-12 2018-02-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
JP5823484B2 (ja) * 2010-07-14 2015-11-25 千寿製薬株式会社 α―ケトアミド誘導体固体分散体
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
WO2012122279A1 (en) 2011-03-08 2012-09-13 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
EP2802354A4 (de) * 2012-01-09 2015-07-29 Virginia Tech Intell Prop Zellulosederivate zur hemmung der kristallisation von schwer wasserlöslichen arzneimitteln
RU2699358C2 (ru) * 2012-05-31 2019-09-05 Мерк Шарп И Доум Корп. Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
US9592294B2 (en) 2013-03-20 2017-03-14 Dow Global Technologies Llc Polyalkoxylated alcohols as excipients for pharmaceutical compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
GB201602579D0 (en) * 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US10738530B2 (en) * 2018-01-16 2020-08-11 Crestron Electronics, Inc. Motor pretensioned roller shade
WO2019193488A1 (en) 2018-04-06 2019-10-10 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
EP3793527A1 (de) * 2018-05-14 2021-03-24 Capsugel Belgium NV Feste darreichungsformen mit hoher wirkstoffbeladung
WO2020099937A2 (en) * 2018-11-14 2020-05-22 Prud'homme, Robert, K. Dihydromyricetin spray-dried dispersion formulations and methods for forming them
EP3982953A4 (de) * 2019-06-14 2023-07-19 The Trustees of Princeton University Formulierungen von dihydromyricetin und einem permeabilitätsmittel
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN114177142B (zh) * 2021-10-28 2023-06-27 瑞普（天津）生物药业有限公司 一种普拉沙星肠溶固体分散体与含有该固体分散体的制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA298245A (en) * 1930-03-11 The Keller Mechanical Engineering Corporation Electric tracer control for lathes
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
ATE159426T1 (de) * 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
TW438786B (en) * 1995-03-28 2001-06-07 Nippon Zoki Pharmaceutical Co Novel benzothiazole derivatives
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
EP0901786B1 (de) 1997-08-11 2007-06-13 Pfizer Products Inc. Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
WO2000018374A1 (en) 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1401503B1 (de) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten

Also Published As

Publication number Publication date
ATE361758T1 (de) 2007-06-15
ES2284871T3 (es) 2007-11-16
US20030104063A1 (en) 2003-06-05
US8703196B2 (en) 2014-04-22
JP2005500313A (ja) 2005-01-06
DE60220049T2 (de) 2007-08-30
WO2003000294A1 (en) 2003-01-03
CA2448864A1 (en) 2003-01-03
CA2448864C (en) 2008-04-22
US20090011024A1 (en) 2009-01-08
EP1401503B1 (de) 2007-05-09
WO2003000294A8 (en) 2003-11-06
US8236328B2 (en) 2012-08-07
BR0210520A (pt) 2004-06-22
AU2002304387A1 (en) 2003-01-08
MXPA03011922A (es) 2004-03-26
EP1401503A1 (de) 2004-03-31
US20120295988A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
ATE400252T1 (de) Pharmazeutische feste dispersionen
GEP20053427B (en) Pharmaceutical Compositions Providing Enhanced Drug Concentrations
EP1269994A3 (de) Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
BR9710984A (pt) Uso de um polìmero, homopolìmero ou copolìmero na obtenção de um medicamento para tratar uma infecção gastrointestinal ou microbiana em um mamìfero
UY27641A1 (es) Composiciones farmacéuticas de dispersiones amorfas de fármacos y materiales que forman microfases lipófilas
AP2002002558A0 (en) Pharmaceutical compositions containing polymer and drug assemblies.
BRPI0109198B8 (pt) emplastro tendo um apoio
ATE433961T1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
DE60238193D1 (de) Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
BRPI0509659A8 (pt) Processo para a preparação de uma composição de polímero de dispersão aquosa
HN2000000267A (es) Oxazolidinonas substituidas y su uso
DE60230340D1 (de) N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
BR0210630A (pt) Sistema fornecedor de liberação prolongada
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
AR025330A1 (es) Combinacion de sustancias activas con clonidina
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
MY140953A (en) Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with pradofloxacin and intrinsically viscous gelling agents as thickening agents
BR0015225A (pt) Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar
ATE500819T1 (de) Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
CL2007003693A1 (es) Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CA2106105A1 (en) Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
WO2001001975A3 (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee